U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit ...

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...
FiercePharma

Myeloid Therapeutics creates new identity after pipeline outgrows its name

Myeloid Therapeutics’ name no longer fits its pipeline. Having expanded beyond the eponymous myeloid cells, the biotech has rebranded as Create Medicines and committed to an R&D strategy that spans in ...
Medscape

Chronic Myeloid Leukemia Highlights From ASH 2025

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.